|
|
||||||||
|
|
|||||||||
|
|
Cardiovascular: Basic ScienceMolecular Targeting - Plaques and Stem Cells |
1 Division of Cardiology, University of California, Irvine School of Medicine, Irvine, California; 2 Bristol-Myers Squibb Medical Imaging, North Billerica, Massachusetts; 3 Division of Cardiovascular Diseases, University of California, San Diego, La Jolla, California
|
|
112
Objectives: Matrix Metalloproteinases (MMP) play an important role in atherosclerotic plaque instability by contributing to positive vascular remodeling and fibrous cap thinning and rupture.
Methods: Using a 99mTc-labeled broad spectrum MMP inhibitor (MPI) and micro-SPECT/micro CT, we evaluated the feasibility of noninvasive imaging of MMP activity in apolipoprotein E deficient (E0, n=14), low density lipoprotein receptor deficient (L0, n=14) mice and wild-type C57BL/6 mice (N=7). The mean age of the mice was 47 ± 3.3 weeks. Of these, 7 E0 and 7 L0 mice received a high cholesterol diet (HCD) for 6 months before imaging. After in vivo imaging, aortas were explanted, ex vivo images acquired and the percent injected dose per gram (%ID/g) MPI uptake determined, followed by histological and immunohistochemical characterization.
Results: MPI uptake was noninvasively visualized in atherosclerotic lesions by micro-SPECT imaging and confirmed by micro CT localization and aortic calcification. %ID/g MPI uptake in each part of aorta was highest in the HCD E0, followed by the HCD-L0, chow-fed E0 and L0. The control mice had minimal MPI uptake. A significant correlation was noted between MPI uptake and MMP-2 (r=.44, p=.10) and -9 (r=.65, p=.008) expression in atherosclerotic plaque.
Conclusions: This study demonstrates the feasibility of using radiolabeled MPI for noninvasive assessment of MMP activity in experimental atherosclerotic models and likelihood of eventual clinical identification of unstable plaques.
| ||||||||||||||||||||||||||||||||||||||